Zobrazeno 1 - 10
of 1 112
pro vyhledávání: '"G. Liva"'
Autor:
D. M. Conti, V. Backer, W. Fokkens, P. Gevaert, A. Peters, G. K. Scadding, I. Pavord, S. Lau, M. Wechsler, X. Bertels, G. Liva, M. Doulaptsi, E. Prokopakis, P. W. Hellings
Publikováno v:
Frontiers in Allergy, Vol 5 (2024)
The European Forum for Research and Education in Allergy and Airways diseases (EUFOREA) organized the first European Biologic Training Course (EBTC) in Brussels on 1st March 2024. The aim of this hybrid EBTC including both face-to-face and web-based
Externí odkaz:
https://doaj.org/article/7a5f37cf82ca4cf0a444065e56a73989
Autor:
Kaiyin Fei, Peter C Taylor, Tom WJ Huizinga, Georg Schett, Matthew J Loza, Chetan S Karyekar, Bei Zhou, Jocelyn H Leu, Qingmin Wang, Keying Ma, Fowzia Ibrahim, Yuan Xiong, Sheng Gao, Sophia G Liva, Jafar Sadik B Shaik, Rohit A Panchakshari, Harman Dhatt, Ricardo Rojo Cella, Carolyn A Cuff
Publikováno v:
RMD Open, Vol 10, Iss 2 (2024)
Objectives To investigate the efficacy, safety, pharmacokinetics and pharmacodynamics of nipocalimab in participants with moderate to severe active rheumatoid arthritis (RA) and inadequate response or intolerance to ≥1 antitumour necrosis factor ag
Externí odkaz:
https://doaj.org/article/e8783e06cebd4815857f9ccfd2c182ba
Autor:
Alyssa Marie M. Castillo, Trang T. Vu, Sophia G. Liva, Min Chen, Zhiliang Xie, Justin Thomas, Bryan Remaily, Yizhen Guo, Uma L. Subrayan, Travis Costa, Timothy H. Helms, Donald J. Irby, Kyeongmin Kim, Dwight H. Owen, Samuel K. Kulp, Thomas A. Mace, Mitch A. Phelps, Christopher C. Coss
Publikováno v:
JCSM Rapid Communications, Vol 4, Iss 2, Pp 232-244 (2021)
Abstract Background Monoclonal antibody (mAb) immune checkpoint inhibitor (ICI) therapies have dramatically impacted oncology this past decade. However, only about one‐third of patients respond to treatment, and biomarkers to predict responders are
Externí odkaz:
https://doaj.org/article/db94475297f14a02937ba2decc4f78d7
Autor:
Sophia G Liva, Yu‐Chou Tseng, Anees M Dauki, Michael G Sovic, Trang Vu, Sally E Henderson, Yi‐Chiu Kuo, Jason A Benedict, Xiaoli Zhang, Bryan C Remaily, Samuel K Kulp, Moray Campbell, Tanios Bekaii‐Saab, Mitchell A Phelps, Ching‐Shih Chen, Christopher C Coss
Publikováno v:
EMBO Molecular Medicine, Vol 12, Iss 2, Pp 1-21 (2020)
Abstract No approved therapy exists for cancer‐associated cachexia. The colon‐26 mouse model of cancer cachexia mimics recent late‐stage clinical failures of anabolic anti‐cachexia therapy and was unresponsive to anabolic doses of diverse and
Externí odkaz:
https://doaj.org/article/e590447d2f534e9b86dfa986d39f3eb8
Autor:
Min Chen, Mitch A. Phelps, Sophia G. Liva, Amir Mortazavi, Craig C. Hofmeister, Jiang Wang, Kristin Dittmar, Christopher C. Coss, Alison Walker
Publikováno v:
European Journal of Drug Metabolism and Pharmacokinetics
Background and Objectives REC-2282 is a novel histone deacetylase inhibitor that has shown antitumor activity in in vitro and in vivo models of malignancy. The aims of this study were to characterize the population pharmacokinetics of REC-2282 (AR-42
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::254ff39f43dd267734ab60338bf6da7c
https://doi.org/10.1007/s13318-021-00722-z
https://doi.org/10.1007/s13318-021-00722-z
Autor:
Thomas A. Mace, Samuel K. Kulp, Yizhen Guo, Sophia G. Liva, Trang Vu, Alyssa Marie M Castillo, Uma L Subrayan, Justin Thomas, Timothy H. Helms, Min Chen, Kyeongmin Kim, Zhiliang Xie, Christopher C. Coss, Travis Costa, Bryan Remaily, Mitch A. Phelps, Donald J. Irby, Dwight H. Owen
Publikováno v:
JCSM Rapid Communications, Vol 4, Iss 2, Pp 232-244 (2021)
Jcsm Rapid Communications
Jcsm Rapid Communications
Background Monoclonal antibody (mAb) immune checkpoint inhibitor (ICI) therapies have dramatically impacted oncology this past decade. However, only about one‐third of patients respond to treatment, and biomarkers to predict responders are lacking.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fe5e047c2fd7517629863afea5696c35
https://doaj.org/article/db94475297f14a02937ba2decc4f78d7
https://doaj.org/article/db94475297f14a02937ba2decc4f78d7
Autor:
Zhenhua Xu, Jocelyn H. Leu, Yan Xu, Ivo Nnane, Sophia G. Liva, Shun Xin Wang‐Lin, Rachel Kudgus‐Lokken, An Vermeulen, Daniele Ouellet
Publikováno v:
Clinical pharmacology and therapeutics.
Therapeutic proteins may first be developed as intravenous (IV) therapies with new subcutaneous (SC) dosage forms being subsequently developed to provide an alternative route of administration. As of August 2022, there have been 9 therapeutic protein
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::acd5888688ce43ac7232bb6cc125a0e2
https://pubmed.ncbi.nlm.nih.gov/36516352
https://pubmed.ncbi.nlm.nih.gov/36516352
Autor:
Mitch A. Phelps, William Blum, Sophia G. Liva, Rebecca B. Klisovic, Bhavana Bhatnagar, Christopher C. Coss, Jiang Wang, Guido Marcucci, Susan Geyer, Katherine Walsh, Ramiro Garzon, Qiuhong Zhao, Alison Walker
Publikováno v:
Leuk Lymphoma
This phase I trial sought to determine a biologically safe and effective dose of AR-42, a novel histone deacetylase inhibitor, which would lead to a doubling of miR-29b prior to decitabine administration. Thirteen patients with previously untreated o
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4a8c0b303d5b593a7d481e7ba3befdc4
https://doi.org/10.1080/10428194.2020.1719095
https://doi.org/10.1080/10428194.2020.1719095
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
D. Bradley Welling, Paul Monk, Jiang Wang, Christopher C. Coss, Douglas W. Sborov, Richard Piekarz, Charles L. Shapiro, Herbert B. Newton, Soun Khountham, Robert Cavaliere, Katharine Collier, Hugo Valencia, Mitch A. Phelps, Erinn M. Hade, Ming Poi, Craig C. Hofmeister, Sophia G. Liva, Amir Mortazavi
Publikováno v:
Cancer Chemother Pharmacol
PURPOSE: Given clinical activity of AR-42, an oral histone deacetylase inhibitor, in hematologic malignancies and preclinical activity in solid tumors, this phase 1 trial investigated the safety and tolerability of AR-42 in patients with advanced sol
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1ed1cd6605799267ec89340db3cb10d9
https://europepmc.org/articles/PMC8162746/
https://europepmc.org/articles/PMC8162746/
